Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast to 2027

October 2018 | 56 pages | ID: P4DCC656C52EN
DelveInsight

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight’s ‘Pulmonary Arterial Hypertension (PAH) - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pulmonary Arterial Hypertension in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

GEOGRAPHY COVERED

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Pulmonary Arterial Hypertension Epidemiology

The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Pulmonary Arterial Hypertension are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Pulmonary Arterial Hypertension Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total Prevalent cases, Sub-type specific prevalent cases and Gender specific prevalence) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total prevalent population of Pulmonary Arterial Hypertension was found to be 70,557 in the year 2016 in 7MM.

REPORT SCOPE

• The report covers detailed overview of Pulmonary Arterial Hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Pulmonary Arterial Hypertension in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by sub-type i.e., Idiopathic PAH, Drug/Toxin Induced, CTD Associated PAH, Portopulmonary Hypertension associated PAH, CHD associated PAH, Heritable PAH and Gender-specific Pulmonary Arterial Hypertension in 7MM

KEY STRENGTHS

• 10 Year Forecast of Pulmonary Arterial Hypertension epidemiology
• 7MM Coverage
• Total Prevalent Cases of PAH
• Prevalent Cases according to segmentation: Sub-type specific & Gender- specific prevalence
• Diagnosed cases of PAH

KEY ASSESSMENTS

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. DISEASE BACKGROUND AND OVERVIEW: PULMONARY ARTERIAL HYPERTENSION (PAH)

2.1. Introduction
2.2. Signs and Symptoms
2.3. Classification of Pulmonary Arterial Hypertension (PAH)
2.4. Functional Classification of PAH
2.5. Etiology
2.6. Risk factors
2.7. Pathophysiology
2.8. Diagnosis

3. EPIDEMIOLOGY AND PATIENT POPULATION

3.1. Key Findings
3.2. Population and Forecast Parameters
3.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH]

4. COUNTRY WISE-EPIDEMIOLOGY OF PULMONARY ARTERIAL HYPERTENSION (PAH)

4.1. The United States
  4.1.1. Total Prevalent Patient Population of PAH in the United States
  4.1.2. Sub-type Specific Prevalence of PAH in the United States
  4.1.3. Gender specific Prevalence of PAH in the United States
4.2. Germany
  4.2.1. Total Prevalent Patient Population of PAH in Germany
  4.2.2. Sub-type Specific Prevalence of PAH in Germany
  4.2.3. Gender specific Prevalence of PAH in Germany
4.3. France
  4.3.1. Total Prevalent Patient Population of PAH in France
  4.3.2. Sub-type Specific Prevalence of PAH in France
  4.3.3. Gender specific Prevalence of PAH in France
4.4. Italy
  4.4.1. Total Prevalent Patient Population of PAH in Italy
  4.4.2. Sub-type Specific Prevalence of PAH in Italy
  4.4.3. Gender specific Prevalence of PAH in Italy
4.5. Spain
  4.5.1. Total Prevalent Patient Population of PAH in Spain
  4.5.2. Sub-type Specific Prevalence of PAH in Spain
  4.5.3. Gender specific Prevalence of PAH in Spain
4.6. The United Kingdom
  4.6.1. Total Prevalent Patient Population of PAH in the UK
  4.6.2. Sub-type Specific Prevalence of PAH in the UK
  4.6.3. Gender specific Prevalence of PAH in the United Kingdom
4.7. Japan
  4.7.1. Total Prevalent Patient Population of PAH in Japan
  4.7.2. Sub-type Specific Prevalence of PAH in Japan
  4.7.3. Gender specific Prevalence of PAH in Japan

5. APPENDIX

5.1. Report Methodology

6. DELVEINSIGHT CAPABILITIES

7. DISCLAIMER

8. ABOUT DELVEINSIGHT

List Of Tables

LIST OF TABLES

Table 1 Total Prevalent Patient Population of PAH in 7MM (2016-2027)
Table 2 Total Prevalent Population of PAH in the United States (2016-2027)
Table 3 Sub-type Specific Prevalence of PAH in the United States (2016-2027)
Table 4 Gender specific Prevalence of PAH in the United States (2016-2027)
Table 5 Total Prevalent Population of PAH in Germany (2016-2027)
Table 6 Sub-type Specific Prevalence of PAH in Germany (2016-2027)
Table 7 Gender specific Prevalence of PAH in Germany (2016-2027)
Table 8 Total Prevalent Population of PAH in France (2016-2027)
Table 9 Sub-type Specific Prevalence of PAH in France (2016-2027)
Table 10 Gender specific Prevalence of PAH in France (2016-2027)
Table 11 Total Prevalent Population of PAH in Italy (2016-2027)
Table 12 Sub-type Specific Prevalence of PAH in Italy (2016-2027)
Table 13 Gender specific Prevalence of PAH in Italy (2016-2027)
Table 14 Total Prevalent Population of PAH in Spain (2016-2027)
Table 15 Sub-type Specific Prevalence of PAH in Spain (2016-2027)
Table 16 Gender specific Prevalence of PAH in Spain (2016-2027)
Table 17 Total Prevalent Population of PAH in the UK (2016-2027)
Table 18 Sub-type Specific Prevalence of PAH in the UK (2016-2027)
Table 19 Gender specific Prevalence of PAH in the UK (2016-2027)
Table 20 Total Prevalent Population of PAH in Japan (2016-2027)
Table 21 Sub-type Specific Prevalence of PAH in Japan (2016-2027)
Table 22 Gender specific Prevalence of PAH in Japan (2016-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Classification of Pulmonary Arterial Hypertension (PAH)
Figure 2: Functional Classification of PAH
Figure 3: Risk Factors of Pulmonary Arterial Hypertension
Figure 4: Pathophysiology of Pulmonary Arterial Hypertension (PAH)
Figure 5: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)
Figure 6: Total Prevalent Patient Population of PAH in 7MM (2016-2027)
Figure 7: Prevalence of PAH in the United States (2016-2027)
Figure 8: Sub-type Specific Prevalence of PAH in the United States (2016-2027)
Figure 9: Gender specific Prevalence of PAH in the United States (2016-2027)
Figure 10: Total Prevalent Population of PAH in Germany (2016-2027)
Figure 11: Sub-type Specific Prevalence of PAH in Germany (2016-2027)
Figure 12: Gender specific Prevalence of PAH in Germany (2016-2027)
Figure 13: Total Prevalent Population of PAH in France (2016-2027)
Figure 14: Sub-type Specific Prevalence of PAH in France (2016-2027)
Figure 15: Gender specific Prevalence of PAH in France (2016-2027)
Figure 16: Total Prevalent Population of PAH in Italy (2016-2027)
Figure 17: Sub-type Specific Prevalence of PAH in Italy (2016-2027)
Figure 18: Gender specific Prevalence of PAH in Italy (2016-2027)
Figure 19: Total Prevalent Population of PAH in Spain (2016-2027)
Figure 20: Sub-type Specific Prevalence of PAH in Spain (2016-2027)
Figure 21: Gender specific Prevalence of PAH in Spain (2016-2027)
Figure 22: Total Prevalent Population of PAH in the UK (2016-2027)
Figure 23: Sub-type Specific Prevalence of PAH in the UK (2016-2027)
Figure 24: Gender specific Prevalence of PAH in the United Kingdom (2016-2027)
Figure 25: Total Prevalent Population of PAH in Japan (2016-2027)
Figure 26: Sub-type Specific Prevalence of PAH in Japan (2016-2027)
Figure 27: Gender specific Prevalence of PAH in Japan (2016-2027)